Preventive prospective of triclosan and triclosan-liposomal nanoparticles against experimental infection with a cystogenic ME49 strain of Toxoplasma gondii

Acta Tropica

Volumn 141, Issue Part A, 2015, Pages 103-111

  El Zawawy, Lobna A ^a   El Said, Doaa ^a   Mossallam, Shereen F ^a   Ramadan, Heba S ^b   Younis, Salwa S ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

Cysts; Liposomes; ME49 avirulent strain; Toxoplasma gondii; Triclosan

Indexed keywords

LIPOSOME; NANOPARTICLE; TOPICAL ANTIINFECTIVE AGENT; TRICLOSAN;

ANIMAL; BRAIN; CYST; DRUG EFFECTS; MOUSE; PARASITOLOGY; PROSPECTIVE STUDY; SCANNING ELECTRON MICROSCOPY; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; TRANSMISSION ELECTRON MICROSCOPY; ULTRASTRUCTURE;

ANIMALS; ANTI-INFECTIVE AGENTS, LOCAL; BRAIN; CYSTS; LIPOSOMES; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PROSPECTIVE STUDIES; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; TRICLOSAN;

EID: 84908689732     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2014.09.020     Document Type: Article

References (62)

1. Allmyr M., Panagiotidis G., Sparve E., Diczfalusy U., Sandborgh-Englund G. Human exposure to triclosan via toothpaste does not change CYP3A4 activity or plasma concentrations of thyroid hormones. Basic Clin. Pharmacol. Toxicol. 2009, 105(5):339-344.
2. Araujo F.G., Huskinson J., Remington J.S., Mazumdar J., Masek K., Striepen B., et al. Remarkable in vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against tachyzoites and tissue cysts of Toxoplasma gondii. Antimicrob. Agents Chemother. 1991, 35(2):293-299.
3. Araujo F.G., Huskinson-Mark J., Gutteridge W.E., Remington J.S. In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii. Antimicrob. Agents Chemother. 1992, 36(2):326-330.
4. Bangham A.D. Development of the liposome concept. Liposomes in Biological Systems 1980, 1-24. John Wiley & Sons, Chichester. G. Gregoridiadis, A.C. Allison (Eds.).
5. Bork S., Yokoyama N., Matsuo T., Claveria F.G., Fujisaki K., Igarashi I. Growth inhibitory effect of triclosan on equine and bovine Babesia parasites. Am. J. Trop. Med. Hyg. 2003, 68(3):334-340.
6. Burkhardt D., Wiesner J., Stoesser N., Ramharter M., Uhlemann A.C., Issifou S., et al. Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro. Int. J. Parasitol. 2007, 37(7):777-785.
7. Burns W.A. Thick Sections: Technique and Applications. Diagnostic Electron Microscopy 1978, 141-166. John Wiley & Sons, New York. G.F. Trump, R.J. Jones (Eds.).
8. Cauchetier E., Paul M., Rivollet D., Fessi H., Astier A., Deniau M. Therapeutic evaluation of free and liposome-encapsulated atovaquone in the treatment of murine leishmaniasis. Int. J. Parasitol. 2000, 30(6):777-783.
9. Cavalcanti M., Mesquita J., Madi K., Feijó D., Miranda I., Heitor S.P., et al. MIF participates in Toxoplasma gondii-induced pathology following oral infection. PLoS ONE 2011, 6(9):e25259.
10. Chew W.K., Segarra I., Ambu S., Mak J.W. Significant reduction of brain cysts caused by Toxoplasma gondii after treatment with spiramycin coadministered with metronidazole in a mouse model of chronic toxoplasmosis. Antimicrob. Agents Chemother. 2012, 56(4):1762-1768.
11. Chew W.K., Wah M.J., Ambu S., Segarra I. Toxoplasma gondii: determination of the onset of chronic infection in mice and the in vitro reactivation of brain cysts. Exp. Parasitol. 2012, 130:22-25.
12. Chirgwin K., Hafner R., Leport C., Remington J., Andersen J., Bosler E.M., et al. Randomized phase II trial of atovaquone with pyrimethamine or sulfadiazine for treatment of toxoplasmic encephalitis in patients with acquired immunodeficiency syndrome: ACTG 237/ANRS 039 Study. Clin. Infect. Dis. 2002, 34(9):1243-1250.
13. Costa I.N., Angeloni M.B., Santana L.A., Barbosa B.F., Silva M.C., Rodrigues A.A., et al. Azithromycin inhibits vertical transmission of Toxoplasma gondii in Calomys callosus (Rodentia: Cricetidae). Placenta 2009, 30(10):884-890.
14. Dass C.R. Drug delivery in cancer using liposomes. Methods Mol. Biol. 2008, 437:177-182.
15. Djurković-Djaković O., Milenković V., Nikolić A., Bobić B., Grujić J. Efficacy of atovaquone combined with clindamycin against murine infection with a cystogenic (Me49) strain of Toxoplasma gondii. J. Antimicrob. Chemother. 2002, 50(6):981-987.
16. Djurković-Djaković O., Djokić V., Vujanić M., Zivković T., Bobić B., Nikolić A., et al. Kinetics of parasite burdens in blood and tissues during murine toxoplasmosis. Exp. Parasitol. 2012, 131:372-376.
17. Dubey J.P., Lindsay D.S., Speer C.A. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin. Microbiol. 1998, 11:267-299.
18. Elsheikha H.M. Congenital toxoplasmosis: priorities for further health promotion action. Public Health 2008, 122:335-353.
19. Faber C., Stallmann H.P., Lyaruu D.M., De Blieck J.M., Bervoets T.J., Van Nieuw Amerongen A., et al. Release of antimicrobial peptide Dhvar-5 from polymethylmethacrylate beads. J. Antimicrob. Chemother. 2003, 51:1359-1364.
20. Fenske D.B., Cullis P.R. Liposomal nanomedicines. Expert Opin. Drug Deliv. 2008, 5(1):25-44.
21. Fichera M.E., Bhopale M.K., Roos D.S. In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii. Antimicrob. Agents Chemother. 1995, 39(7):1530-1537.
22. Fichera M.E., Roos D.S. A plastid organelle as a drug target in apicomplexan parasites. Nature 1997, 390(6658):407-409.
23. Fung H.B., Kirschenbaum H.L. Treatment regimens for patients with toxoplasmic encephalitis. Clin. Ther. 1996, 18:1037-1056.
24. Goodman C.D., McFadden G.I. Fatty acid biosynthesis as a drug target in apicomplexan parasites. Curr. Drug Targets 2007, 8(1):15-30.
25. Guillén J., Bernabeu A., Shapiro S., Villalaín J. Location and orientation of triclosan in phospholipid model membranes. Eur. Biophys. J. 2004, 33(5):448-453.
26. Heath R.J., Rubin J.R., Holland D.R., Zhang E., Snow M.E., Rock C.O. Mechanism of triclosan inhibition of bacterial fatty acid synthesis. J. Biol. Chem. 1999, 274(16):11110-11114.
27. Higgins J., Pinjon E., Oltean H.N., White T.C., Kelly S.L., Martel C.M., et al. Triclosan antagonizes fluconazole activity against Candida albicans. J. Dent. Res. 2012, 91(1):65-70.
28. Katlama C., De Wit S., O'Doherty E., Van Glabeke M., Clumeck N. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin. Infect. Dis. 1996, 22(2):268-275.
29. Kavitha N., Noordin R., Kit-Lam C., Sasidharan S. Real time anti-Toxoplasma gondii activity of an active fraction of Eurycoma longifolia root studied by in situ scanning and transmission electron microscopy. Molecules 2012, 17(8):9207-9219.
30. Khaw M., Panosian C.B. Human antiprotozoal therapy: past, present, and future. Clin. Microbiol. Rev. 1995, 8(3):427-439.
31. Kirby C., Gregoriadis G. Dehydration-rehydration vesicles: a simple method for high yield drug entrapment in liposomes. Biotechnology 1984, 2:979-984.
32. Kur J., Holec-Gasior L., Hiszczyńska-Sawicka E. Current status of toxoplasmosis vaccine development. Expert Rev. Vaccines 2009, 8(6):791-808.
33. Lai B.S., Witola W.H., El Bissati K., Zhou Y., Mui E., Fomovska A., et al. Molecular target validation, antimicrobial delivery, and potential treatment of Toxoplasma gondii infections. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(35):14182-14187.
34. Lasic D.D. Novel applications of liposomes. Trends Biotechnol. 1998, 16(7):307-321.
35. Lu J.Z., Muench S.P., Allary M., Campbell S., Roberts C.W., Mui E., et al. Type I and type II fatty acid biosynthesis in Eimeria tenella: enoyl reductase activity and structure. Parasitology 2007, 134(14):1949-1962.
36. Luft B.J., Remington J.S. Toxoplasmic encephalitis in AIDS (AIDS commentary). Clin. Infect. Dis. 1992, 15:211-222.
37. Maestrelli F., Mura P., Alonso M.J. Formulation and characterization of triclosan sub-micron emulsions and nanocapsules. J. Microencapsul. 2004, 21:857-864.
38. Matuschka F.R. The effect of sulfomethoxypyrazine-pyrimethamine therapy on the fine structure of Toxoplasma gondii-cysts in the brain of Mastomys natalensis. Scanning and transmission electron microscopical investigations. Zentralbl. Bakteriol. Orig. A 1977, 238(3):419-429.
39. McFadden G.I., Roos D.S. Apicomplexan plastids as drug targets. Trends Microbiol. 1999, 7(8):328-333.
40. McLeod R., Muench S., Rafferty J., Kyle D., Mui E., Kirisits M., et al. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int. J. Parasitol. 2001, 31:109-113.
41. Mou Z., He Y., Dai Y., Liu X., Li J. Deficiency in fatty acid synthase leads to premature cell death and dramatic alterations in plant morphology. Plant Cell 2000, 12(3):405-418.
42. Nagamune K., Beatty W.L., Sibley L.D. Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii. Eukaryot. Cell 2007, 6(11):2147-2156.
43. Nguyen B.T., Stadtsbaeder S. Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole), pyrimethamine-sulphadiazine and spiramycin during avirulent infection with Toxoplasma gondii (Beverley strain) in mice. Br. J. Pharmacol. 1983, 9(4):923-928.
44. Paul K.S., Bacchi C.J., Englund P.T. Multiple triclosan targets in Trypanosoma brucei. Eukaryot. Cell 2004, 3(4):855-861.
45. Paul K.B., Hedge J.M., DeVito M.J., Crofton K.M. Short-term exposure to triclosan decreases thyroxine in vivo via upregulation of hepatic catabolism in young long-evans rats. Toxicol. Sci. 2010, 113(2):367-379.
46. Pereira-Chioccola V.L., Vidal J.E., Su C. Toxoplasma gondii infection and cerebral toxoplasmosis in HIV-infected patients. Future Microbiol. 2009, 4(10):1363-1379.
47. Perozzo R., Kuo M., Sidhu A.S., Valiyaveettil J.T., Bittman R., Jacobs W.R., et al. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J. Biol. Chem. 2002, 277:13106-13114.
48. Ralph S.A., Van Dooren G.G. Tropical infectious diseases: metabolic maps and functions of the Plasmodium falciparum apicoplast. Nat. Rev. Microbiol. 2004, 2:203-216.
49. Ramya T.N., Mishra S., Karmodiya K., Surolia N., Surolia A. Inhibitors of nonhousekeeping functions of the apicoplast defy delayed death in Plasmodium falciparum. Antimicrob. Agents Chemother. 2007, 51(1):307-316.
50. Rodricks J.V., Swenberg J.A., Borzelleca J.F., Maronpot R.R., Shipp A.M. Triclosan: a critical review of the experimental data and development of margins of safety for consumer products. Crit. Rev. Toxicol. 2010, 40(5):422-484.
51. Rodriguez J.B., Szajnman S.H. New antibacterials for the treatment of toxoplasmosis; a patent review. Expert Opin. Ther. Pat. 2012, 22(March (3)):311-333.
52. Samuel B.U., Hearn B., Mack D., Wender P., Rothbard J., Kirisits M.J., et al. Delivery of antimicrobials into parasites. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(24):14281-14286.
53. Schöler N., Krause K., Kayser O., Müller R., Borner K., Hahn H., et al. Atovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosis. Antimicrob. Agents Chemother. 2001, 45(6):1771-1779.
54. Sharma S., Ramya T.N.C., Surolia A., Surolia N. Triclosan as a systemic antibacterial agent in a mouse model of acute bacterial challenge. Antimicrob. Agents Chemother. 2003, 47(12):3859-3866.
55. Sordet F., Aumjaud Y., Fessi H., Derouin F. Assessment of the activity of atovaquone-loaded nanocapsules in the treatment of acute and chronic murine toxoplasmosis. Parasite 1998, 5(3):223-229.
56. Sullivan W.J., Jeffers V. Mechanisms of Toxoplasma gondii persistence and latency. FEMS Microbiol. Rev. 2012, 36:717-733.
57. Surolia N., Surolia A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat. Med. 2001, 7:167-173.
58. Tanaka T., Maeda H., Matsuo T., Boldbattar D., Umemiya-Shirafuji R., et al. Parasiticidal activity of Haemaphysalis longicornis longicin P4 peptide against Toxoplasma gondii. Peptides 2012, 34(1):242-250.
59. Tang M.F., Lei L., Guo S.R., Huang W.L. Recent progress in nanotechnology for cancer therapy. Chin. J. Cancer. 2010, 29(9):775-780.
60. Vandhana S., Deepa P.R., Aparna G., Jayanthi U., Krishnakumar S. Evaluation of suitable solvents for testing the anti-proliferative activity of triclosan - a hydrophobic drug in cell culture. Indian J. Biochem. Biophys. 2010, 47(3):166-171.
61. Villalaín J., Mateo C.R., Aranda F.J., Shapiro S., Micol V. Membranotropic effects of the antibacterial agent triclosan. Arch. Biochem. Biophys. 2001, 390(1):128-136.
62. Waller R.F., Ralph S.A., Reed M.B., Su V., Douglas J.D., Minnikin D.E., et al. A type II pathway for fatty acid biosynthesis presents drug targets in Plasmodium falciparum. Antimicrob. Agents Chemother. 2003, 47(1):297-301.